Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED t...

por Zhao, Li-Min, Zhan, Ze-Lin, Qiu, Mei
Publicado 2021

Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials

por Qiu, Mei, Zhao, Li-Min, Zhan, Ze-Lin
Publicado 2021

Does Combination Therapy With SGLT2 Inhibitors and Renin–Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?

por Zhao, Li-Min, Zhang, Miao, Zhan, Ze-Lin, Qiu, Mei
Publicado 2021

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

por Zhao, Li-Min, Zhan, Ze-Lin, Ning, Jie, Qiu, Mei
Publicado 2022

Meta‐analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF

por Qiu, Mei, Ding, Liang‐Liang, Zhan, Ze‐Lin, Zhou, Hai‐Rong
Publicado 2021

Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analy...

por Qiu, Mei, Ding, Liang-Liang, Zhan, Ze-Lin, Zhou, Hai-Rong
Publicado 2021

Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM

por Li, Lu-Feng, Ding, Liang-Liang, Zhan, Ze-Lin, Qiu, Mei
Publicado 2021

Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials

por Zhao, Li-Min, Huang, Jia-Nan, Qiu, Mei, Ding, Liang-Liang, Zhan, Ze-Lin, Ning, Jie
Publicado 2021